| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
NITD-349 manufacturers
- NITD-349
-
- $44.00
-
2026-09-10
- CAS:1473450-62-2
- Purity: 99.89%
- Supply Ability: 10g
- NITD-349
-
- $44.00
-
2026-07-14
- CAS:1473450-62-2
- Purity: 99.89%
- Supply Ability: 10g
|
| | NITD-349 Basic information |
| Product Name: | NITD-349 | | Synonyms: | NITD-349;1H-Indole-2-carboxamide, N-(4,4-dimethylcyclohexyl)-4,6-difluoro-;inhibit,Bacterial,NITD349,NITD-349,NITD 349,Inhibitor;N-(4,4-Dimethylcyclohexyl)-4,6-difluoro-1H-indole-2-carboxamide;NITD-349, 10 mM in DMSO | | CAS: | 1473450-62-2 | | MF: | C17H20F2N2O | | MW: | 306.35 | | EINECS: | | | Product Categories: | | | Mol File: | 1473450-62-2.mol |  |
| | NITD-349 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : ≥ 310 mg/mL (1011.91 mM) | | form | Solid | | color | White to off-white |
| | NITD-349 Usage And Synthesis |
| Uses | NITD-349, shows bactericidal activity against in vitro replicating Mycobacterium tuberculosis (Mtb) and also are active against intramacrophage Mtb. | | in vivo | In the acute murine efficacy modelNITD-349 shows favorable oral pharmacokinetic (PK) properties in rodents and dogs and are efficacious in mouse models of both acute and chronic Mycobacterium tuberculosisinfection. In the acute murine efficacy model, treatment of mice with NITD-349 at doses of 12.5 and 50 mg/kg resulted in 0.9- and 3.4-log CFU reduction in lung tissue. In an established infection mouse model, after 2 weeks of treatment, the efficacy of NITD-349 is comparable to the first-line TB drug rifampicin and is better than ethambutol. Four weeks of treatment at 100 mg/kg with NITD-349 results in 2.38-log CFU reductions[1]. |
| | NITD-349 Preparation Products And Raw materials |
|